Renal Cell Cancer Clinical Trial
Official title:
A Clinical Trial to Evaluate the Effect of Neoadjuvant MK-3475 (Pembrolizumab) Therapy on Intratumoral Immune Infiltrates in Renal Cell Cancer (RCC) Patients Undergoing Surgical Resection
This study will examine the effect of treatment with the neoadjuvant antibody pembrolizumab (MK-3475) on tumors of participants with renal cell cancer (RCC). The primary hypotheses are that pembrolizumab is well tolerated in participants undergoing RCC tumor resection; and that pembrolizumab will stimulate a 2-fold or greater increase in intratumoral lymphocytic infiltration in at least 30% of participants with RCC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01392729 -
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)
|
N/A | |
| Completed |
NCT00694096 -
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
|
Phase 1 | |
| Completed |
NCT00520403 -
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
|
Phase 2 | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Completed |
NCT00172003 -
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
|
Phase 4 | |
| Completed |
NCT02493751 -
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
|
Phase 1 | |
| Recruiting |
NCT01967407 -
IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.
|
Phase 1/Phase 2 | |
| Completed |
NCT00509704 -
Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
|
N/A | |
| Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04535921 -
Fear of Cancer Recurrence in Genitourinary Cancer
|
||
| Recruiting |
NCT04620603 -
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01829841 -
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
|
Phase 2 | |
| Completed |
NCT01122615 -
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
|
Phase 1 | |
| Completed |
NCT00979329 -
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
|
N/A | |
| Active, not recruiting |
NCT02429440 -
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06362369 -
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02684006 -
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
|
Phase 3 | |
| Completed |
NCT02375776 -
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
|
N/A | |
| Completed |
NCT01598597 -
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
|
N/A | |
| Completed |
NCT00465179 -
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
|
Phase 2 |